149 related articles for article (PubMed ID: 2040873)
1. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites.
De Wit R; Hoek FJ; Bakker PJ; Veenhof CH
J Intern Med; 1991 May; 229(5):463-6. PubMed ID: 2040873
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
[TBL] [Abstract][Full Text] [Related]
3. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
4. A new biomarker in monitoring breast cancer: CA 549.
Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
6. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.
Miserez AR; Günes I; Müller-Brand J; Walther E; Fridrich R; Mäcke H
Eur J Cancer; 1991; 27(2):126-31. PubMed ID: 1827273
[TBL] [Abstract][Full Text] [Related]
8. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
9. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
Ferroni P; Szpak C; Greiner JW; Simpson JF; Guadagni F; Johnston WW; Colcher D
Int J Cancer; 1990 Sep; 46(3):445-51. PubMed ID: 2394511
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
11. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
12. A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancer.
de Wit R; Hoek FJ; Bakker PJ; Veenhof CH
Ann Oncol; 1992 Apr; 3(4):314-5. PubMed ID: 1390307
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of metastatic breast cancer patients with a mucin-like carcinoma-associated antigen: comparison to CA 15.3 and carcinoembryonic antigen.
Bieglmayer C; Szepesi T; Neunteufel W
Cancer Lett; 1988 Nov; 42(3):199-206. PubMed ID: 2461250
[TBL] [Abstract][Full Text] [Related]
16. CA-15.3, TPA and MCA as markers for breast cancer.
Barak M; Steiner M; Finkel B; Abrahamson J; Antal S; Gruener N
Eur J Cancer; 1990; 26(5):577-80. PubMed ID: 2144745
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
Jezersek B; Cervek J; Rudolf Z; Novaković S
Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
[TBL] [Abstract][Full Text] [Related]
18. [The value of tumor markers CA 15-3 and CEA in breast cancer].
Buck I; Lindner C; Böge K; Kitschke HJ
Arch Gynecol Obstet; 1989; 245(1-4):674-7. PubMed ID: 2802753
[TBL] [Abstract][Full Text] [Related]
19. Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA.
Boccardo F; Bombardieri E; Zanardi S; Valenti G; Zanaboni F; Valtolina M; Seregni E; Crippa F
Int J Biol Markers; 1991; 6(1):12-20. PubMed ID: 1856512
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
